Disease diversity and FLT3 mutations

被引：5
|
作者：
Smith, Catherine Choy [1 ]
机构：
[1] Univ Calif San Francisco, Dept Med, Div Hematol Oncol, San Francisco, CA 94143 USA
来源：
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA | 2013年 / 110卷 / 52期
关键词：
ACUTE MYELOID-LEUKEMIA; INTERNAL TANDEM DUPLICATION; GASTROINTESTINAL STROMAL TUMORS; KINASE DOMAIN MUTATIONS; THERAPEUTIC TARGET; ITD MUTATIONS; RESISTANCE; VALIDATION; ACTIVATION; GEFITINIB;
D O I：
10.1073/pnas.1320579110
中图分类号：
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
引用
收藏
页码：20860 / 20861
页数：2
相关论文
共 50 条
  • [1] Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations
    Tarver, Theodore C.
    Hill, Jason E.
    Rahmat, Leena
    Perl, Alexander E.
    Bahceci, Erkut
    Mori, Kenichi
    Smith, Catherine C.
    BLOOD ADVANCES, 2020, 4 (03) : 514 - 524
  • [2] Gilteritinib: potent targeting of FLT3 mutations in AML
    Levis, Mark
    Perl, Alexander E.
    BLOOD ADVANCES, 2020, 4 (06) : 1178 - 1191
  • [3] Identification of novel FLT3 kinase inhibitors
    Pauwels, Daphnie
    Klaassen, Hugo
    Lahortiga, Idoya
    Kilonda, Amuri
    Jacobs, Kris
    Sweron, Bram
    Corbau, Romuald
    Chaltin, Patrick
    Marchand, Arnaud
    Cools, Jan
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2013, 63 : 713 - 721
  • [4] Co-expression of wild-type FLT3 attenuates the inhibitory effect of FLT3 inhibitor on FLT3 mutated leukemia cells
    Chen, Fangli
    Ishikawa, Yuichi
    Akashi, Akimi
    Naoe, Tomoki
    Kiyoi, Hitoshi
    ONCOTARGET, 2016, 7 (30) : 47018 - 47032
  • [5] FLT3 mutations and leukaemia
    Kottaridis, PD
    Gale, RE
    Linch, DC
    BRITISH JOURNAL OF HAEMATOLOGY, 2003, 122 (04) : 523 - 538
  • [6] FLT3 Mutations in Acute Myeloid Leukemia: Key Concepts and Emerging Controversies
    Kennedy, Vanessa E.
    Smith, Catherine C.
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [7] Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia
    Mori, Masamichi
    Kaneko, Naoki
    Ueno, Yoko
    Yamada, Masaki
    Tanaka, Ruriko
    Saito, Rika
    Shimada, Itsuro
    Mori, Kenichi
    Kuromitsu, Sadao
    INVESTIGATIONAL NEW DRUGS, 2017, 35 (05) : 556 - 565
  • [8] Molecular Characterization of FLT3 Mutations in Acute Leukemia Patients
    Ishfaq, Mariam
    Malik, Arif
    Faiz, Mariam
    Sheikh, Ishfaq Ahmad
    Asif, Muhammad
    Khan, Muhammad Nasrullah
    Qureshi, Muhammad Saeed
    Zahid, Sara
    Manan, Abdul
    Arooj, Mahwish
    Qazi, Mahmood Husain
    Chaudhary, Adeel
    Alqahtani, Mohammed Hussain
    Rasool, Mahmood
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2012, 13 (09) : 4581 - 4585
  • [9] Mutation spectrum of FLT3 and significance of non-canonical FLT3 mutations in haematological malignancy
    Ge, Shuai-Shuai
    Qiu, Qiao-Cheng
    Dai, Hai-Ping
    Shen, Xiang-Dong
    Wu, Tian-Mei
    Du, Jia-Hui
    Wan, Chao-Ling
    Shen, Hong-Jie
    Wu, De-Pei
    Xue, Sheng-Li
    Liu, Song-Bai
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, : 539 - 549
  • [10] A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations
    Yamaura, Takeshi
    Nakatani, Toshiyuki
    Uda, Ken
    Ogura, Hayato
    Shin, Wigyon
    Kurokawa, Naoya
    Saito, Koichi
    Fujikawa, Norie
    Date, Tomomi
    Takasaki, Masaru
    Terada, Daisuke
    Hirai, Atsushi
    Akashi, Akimi
    Chen, Fangli
    Adachi, Yoshiya
    Ishikawa, Yuichi
    Hayakawa, Fumihiko
    Hagiwara, Shinji
    Naoe, Tomoki
    Kiyoi, Hitoshi
    BLOOD, 2018, 131 (04) : 426 - 438
12345